Milestones

1. European patent application: Pharmaceutical composition for preventing or treating bronchopulmonary dysplasia by the intravenous route in repeated doses. Priority date 21 March 2023. Application number: EP23382262

2. Analysis of the results of the independent clinical trial PULMESCEL-I and design of the phase II clinical trial evaluating the safety of cord mesenchymal cell therapy in preterm infants at high risk of bronchopulmonary dysplasia.

3. Cruz-Utrilla A, Gallego-Zazo N, Tenorio-Castaño JA, Guillén I, Torrent-Vernetta A, Moya-Bonora A, Labrandero C, Rodríguez-Monte MEG, Rodríguez-Ogando A, Rey MDMRVD, Espín J, Plata-Izquierdo B, Álvarez-Fuente M, Moreno-Galdó A, Escribano-Subias P, Marín MJDC. Clinical Implications of the Genetic Background in Pediatric Pulmonary Arterial Hypertension: Data from the Spanish REHIPED Registry. Int J Mol Sci. 2022; 23(18):10433. doi: 10.3390/ijms231810433. PMID: 36142358

4. Otheo E, Rodríguez M, Moraleda C, Domínguez-Rodríguez S, Martín MD, Herreros ML, Vázquez C, Folgueira MD, Pérez-Rivilla A, Jensen J, López A, Berzosa A, Sanz de Santaeufemia FJ, Jiménez AB, Sainz T, Llorente M, Santos M, Garrote E, Muñoz C, Sánchez P, Illán M, Coca A, Barrios A, Pacheco M, Arquero C, Gutiérrez L, Epalza C, Rojo P, Serna-Pascual M, Mota I, Moreno S, Galán JC, Tagarro A; VALS-DANCE and PCAPE Working Groups. Viruses and Mycoplasma pneumoniae are the main etiological agents of community-acquired pneumonia in hospitalized pediatric patients in Spain. Pediatr Pulmonol. 2022; 57(1):253-263. doi: 10.1002/ppul.25721. PMID: 34633153.

5. Tagarro A, Moraleda C, Domínguez-Rodríguez S, Rodríguez M, Martín MD, Herreros ML, Jensen J, López A, Galán JC, Otheo E; VALS-DANCE Study Group. A Tool to Distinguish Viral From Bacterial Pneumonia. Pediatr Infect Dis J. 2022; 41(1):31-36. doi: 10.1097/INF.0000000000003340. PMID: 34524234.